AMY PARISI: Open Payments
NPI 1053836429 · NEWARK, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$281 in 13 payments from 8 companies in 2025. Trend: 2023 $48 · 2024 $231 · 2025 $281
Food & beverage: $281
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 4 | $90 |
| ABBVIE INC. | 2 | $51 |
| Neurocrine BioSciences, Inc. | 2 | $29 |
| Lundbeck LLC | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $22 |
| Novo Nordisk Inc | 1 | $19 |
| Tris Pharma Inc | 1 | $18 |
Products named: REXULTI, VRAYLAR, INGREZZA, TRINTELLIX, ABILIFY MAINTENA, CAPLYTA, Wegovy, Dyanavel XR.
Industry payments across DE — which companies pay providers there.
